Shorter hepatitis c treatment may be just as effective
NCT ID NCT07702396
First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time
Summary
This study tests whether 12 weeks of a three-drug antiviral combination works as well as 24 weeks for curing hepatitis C in people with chronic liver disease. Researchers will enroll 192 patients who have not been treated before and randomly assign them to either the shorter or longer course. The main goal is to see if the virus stays undetectable 12 weeks after treatment ends, which would indicate a cure.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- a combination of sofosbuvir, daclatasvir, and ribavirin
- What this could lead to
- If 12 weeks works as well as 24, it could simplify hepatitis C treatment, reduce side effects, and lower costs for patients worldwide.
- What could go wrong
- This is a single-center study with 192 patients, so results may not apply to everyone. The shorter course might be less effective in some patients, and ribavirin can cause anemia.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
192 people
The number who actually took part.
- Started
-
Jan 2024
- Finished
-
Sep 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
To include the patients in the study, we screened the high-risk population which included IV drug abusers, positive family history, history of blood transfusions and tooth extraction. We excluded the patients who had HCC, decompensated cirrhosis, CLD other than HCV, HCV treatment failure or HCV Relapse, chronic HBV or HIV infection, alanine aminotransferase (ALT) ≥ 5 x upper limit of normal, total bilirubin ≥ 2 mg/dL, international normalized ratio ≥ 1.7, albumin ≤ 3.5 g/dL, hemoglobin ≤ 12 g/dL (females) or ≤ 13 g/dL (males), absolute neutrophil count ≤ 1.5 x 109 cells/L (≤ 1.2 x 109 cells/L for patients of black race); platelets ≤ 90 x 109 cells/L, creatinine clearance ≤ 50 mL/min, alpha fetoprotein \> 100 ng/mL
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Heptatitis C are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Indus Hospital and Health Network
Karachi, 75510, Pakistan